Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael McCollum

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
American Journal of Disaster Medicine|February 15, 2008
Activating physicians within a hospital emergency plan: a concept whose time has come?Kristine M Gebbie, Steve Silber, Michael McCollum, et al.
Gynecologic Oncology|April 2, 2019
Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancerAngeles Alvarez Secord, Michael McCollum, Brittany A Davidson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2023
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E TrialShannon N Westin, Kathleen Moore, Hye Sook Chon, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
American Journal of Disaster Medicine|February 15, 2008
Activating physicians within a hospital emergency plan: a concept whose time has come?Kristine M Gebbie, Steve Silber, Michael McCollum, et al.
Gynecologic Oncology|April 2, 2019
Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancerAngeles Alvarez Secord, Michael McCollum, Brittany A Davidson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2023
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E TrialShannon N Westin, Kathleen Moore, Hye Sook Chon, et al.
Pageof 1